Immunogenicity and immune tolerance coagulation Factors VIIi and IX
Rup, B.
Developments in Biologicals 112: 55-59
2003
ISSN/ISBN: 1424-6074 PMID: 12762504 Document Number: 555701
Some of the major issues related to the development and control of antibodies that occur during treatment of haemophilia with replacement factors (Factor VIII and Factor IX) are reviewed. Information on analytical issues, immunogenicity, and immune tolerance may be applicable to the study of other therapeutic proteins. Conversely, new information obtained from evaluation of other therapeutic protein products may address issues that remain unresolved for Factor VIII and FIX replacement therapy.
Document emailed within 1 workday
Related Documents
DiMichele, D.; Kroner, B. 2000: The maintenance of tolerance after successful immune tolerance induction in hemophilia A and B: the North American Registry. Factor VIII/IX Subcommittee of the International Society for Thrombosis and Hemostasis Haematologica 85(10 Suppl): 40Mariani, G.; Hilgartner, M.; Thompson, A.R.; Tusell, J.; Manco-Johnson, M.; Ghirardini, A.; Bellocco, R.; Brackmann, H.H. 1995: Immune tolerance to Factor VIII: the international registry data Advances in Experimental Medicine and Biology 386: 201-208
Ewing, N.P. 1990: Induction of immune tolerance with factor VIIi concentrate in patients with hemophilia a and inhibitors Progress in Clinical and Biological Research 324: 59-68
Landolfi, R.; de Cristofaro, R.; Lazzareschi, I.; Riccardi, R.; Mariani, G. 2000: Immune tolerance by intermittent factor VIIi boluses in two high responder hemophilia a patients Haematologica 85(10 Suppl): 73-74
Scharf, R.; Kucharski, W.; Lopaciuk, S.; Celińska, W.; Dmytrow, A.; Domański, K.; Gonet, S.; Miastkowski, Z.; Nowakowska, I.; Przybylski, A. 1991: Preliminary experience with achieving immune tolerance in patients with hemophilia a and circulating factor VIIi inhibitor Acta Haematologica Polonica 22(1): 92-99
Brakman, G.G. 1993: The occurrence of immunological tolerance to inhibitors of factors VIIi and IX in hemophilia patients Gematologiia i Transfuziologiia 38(2): 18-20
Ambrus, J.L.; Courey, N.G.; Browne, B.J.; Mink, I.B.; Moore, R.H.; Ambrus, C.M. 1977: Progestational agents and blood coagulation. VIII. Effect of low-dose, alternate-day, estrogen-progestin combinations on blood coagulation factors in man, with a special note on the effect of freezing of blood samples American Journal of Obstetrics and Gynecology 128(2): 161-166
Liebe, S. 1982: Activation of the antihemophilic globulin a (factor VIII). 2. Effect of ampholine on the course of blood coagulation and the molecular conformation of factor VIIi Zeitschrift für die Gesamte Innere Medizin und ihre Grenzgebiete 37(4): 110-116
Scheibel, E.; Ingerslev, J.; Dalsgaard-Nielsen, J.; Stenbjerg, S.; Knudsen, J.B. 1987: Continuous high-dose factor VIII for the induction of immune tolerance in haemophilia A patients with high responder state: a description of eleven patients treated Thrombosis and Haemostasis 58(4): 1049-1052
Allersma, D.P.; Smid, W.M.; van der Does, J.A.; van der Meer, J.; Briët, E. 1996: Effects of chronic factor VIII substitution on immune parameters in HIV seronegative haemophiliacs: a comparison between cryoprecipitate and factor VIII concentrate Thrombosis and Haemostasis 75(2): 261-266
Mahasandana, C.; Suvatte, V.; Püng-amritt, P.; Tuchinda, S. 1979: Von Willebrand's disease: studies of platelet functions, factor VIII procoagulant activity (F VIII C) and factor VIII-related antigen (F VIII RAg) in three families Southeast Asian Journal of Tropical Medicine and Public Health 10(2): 243-247
Lutze, G.; Schlote, A.; Mittler, U. 1980: Determination of coagulation factor VIIi inhibitors Zeitschrift für die Gesamte Innere Medizin und ihre Grenzgebiete 35(8): 330-336
Kaufman, R.J.; Pipe, S.W.; Tagliavacca, L.; Swaroop, M.; Moussalli, M. 1997: Biosynthesis, assembly and secretion of coagulation factor VIII Blood Coagulation and Fibrinolysis 8(Suppl. 2): S3-S14
Kaufman, R.J.; Pipe, S.W.; Tagliavacca, L.; Swaroop, M.; Moussalli, M. 1997: Biosynthesis, assembly and secretion of coagulation factor VIIi Blood Coagulation and Fibrinolysis: An International Journal in Haemostasis and Thrombosis 8(Suppl 2): S3-14
Eis-Hübinger, A.M.; Sasowski, U.; Brackmann, H.H.; Kaiser, R.; Matz, B.; Schneweis, K.E. 1996: Parvovirus B19 DNA is frequently present in recombinant coagulation factor VIIi products Thrombosis and Haemostasis 76(6): 1120
Jandinski, J.J.; Scott, D.W. 1979: Role of self carriers in the immune response and tolerance. IV. Active T cell suppression in the maintenance of B cell tolerance to a "T-independent" antigen Journal of Immunology 123(6): 2447-2450
Maimunkov, K.; Tsekov, M.; Delibasheva, A. 1971: Blood coagulation in myocardial infarct and changes in coagulation factors during anticoagulant treatment Vutreshni Bolesti 10(5): 44-51
Muncunill, J.; Forner, N.; Morey, M.; Galmés, A.; Vanrell, L.; Besalduch, J. 1991: Infective morbidity of replacement therapy in congenital coagulation deficiencies and its effects on demand of coagulation factors Medicina Clinica 97(8): 287-291
Jorquera, J.I.; Carmona, E.; Aznar, J.A.; Peiró, A.; Sánchez-Cuenca, J.M. 1985: A standardized method for measuring anti-F VIII: C inhibitors in haemophilia a by coagulation inhibition in agarose gel Thrombosis and Haemostasis 54(2): 377-380
Tran, T.H.; Duckert, F. 1983: Dissociation of factor VIIi procoagulant antigen VIII:CAg and factor VIIi related antigen VIIIR:Ag by EDTA - influence of divalent cation on the binding of VIII:CAg and VIIIR:Ag Thrombosis and Haemostasis 50(2): 547-551